髓源性抑制细胞
肿瘤微环境
巨噬细胞移动抑制因子
免疫系统
癌症研究
川东北74
CD8型
髓样
免疫学
免疫疗法
生物
细胞因子
抑制器
癌症
遗传学
MHC I级
作者
Tyler Joseph Alban,Defne Bayık,Balint Otvos,Anja Rabljenovic,Lin Leng,Jia-Shiun Leu,Gustavo A. Roversi,Adam J. Lauko,Arbaz A. Momin,Alireza Mohammad Mohammadi,David M. Peereboom,Manmeet Singh Ahluwalia,Kazuko Matsuda,Kyuson Yun,Richard Bucala,Michael A. Vogelbaum,Justin Durla Lathia
标识
DOI:10.3389/fimmu.2020.01191
摘要
The application of tumor immunotherapy to glioblastoma (GBM) is limited by an unprecedented degree of immune suppression due to factors that include high numbers of immune suppressive myeloid cells, the blood brain barrier, and T cell sequestration to the bone marrow. We previously identified an increase in immune suppressive myeloid-derived suppressor cells (MDSCs) in GBM patients, which correlated with poor prognosis and was dependent on macrophage migration inhibitory factor (MIF). Here we examine the MIF signaling axis in detail in murine MDSC models, GBM-educated MDSCs and human GBM. We found that the monocytic subset of MDSCs (M-MDSCs) expressed high levels of the MIF cognate receptor CD74 and was localized in the tumor microenvironment. In contrast, granulocytic MDSCs (G-MDSCs) expressed high levels of the MIF non-cognate receptor CXCR2 and showed minimal accumulation in the tumor microenvironment. Furthermore, targeting M-MDSCs with Ibudilast, a brain penetrant MIF-CD74 interaction inhibitor, reduced MDSC function and enhanced CD8 T cell activity in the tumor microenvironment. These findings demonstrate the MDSC subsets differentially express MIF receptors and may be leveraged for specific MDSC targeting.
科研通智能强力驱动
Strongly Powered by AbleSci AI